Catalyst Wire Dossier Catalyst Wire Dossier

BIWA-4 (186Re-labeled humanized monoclonal antibody)

BIWA-4 · Boehringer Ingelheim
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for BIWA-4 (186Re-labeled humanized monoclonal antibody), covering 2014-07-30 to 2014-07-30. Get the full timeline:

Most recent: Clinical Trial Update: Biodistribution Study With 186 Re-labelled Humanised Monoclonal Antibody BIWA 4 in Patients With Non-small Cell Lung Cancer [Phase 1]

See pricing